AACE Consensus StatementAmerican Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement - Executive Summary
Section snippets
EXECUTIVE SUMMARY
This new algorithm for the comprehensive management of persons with type 2 diabetes mellitus (T2DM) has been developed to provide clinicians with a practical guide that considers the whole patient, the spectrum of risks and complications for the patient, and evidence-based approaches to treatment. In addition to advocating for gly- cemic control so as to reduce microvascular complications, this document focuses on obesity and prediabetes as the underlying risk factors for diabetes and
DISCLOSURE
Dr. Alan J. Garber reports that he is on the Advisory Board for Novo Nordisk, Merck, Halozyme, Janssen, Takeda, and Vivus. He is a speaker for Novo Nordisk, Merck, Santarus, Janssen, and Vivus. He is also a consultant for Novo Nordisk, Merck, Santarus, Takeda, Tethys, and Vivus.
Dr. Martin Julian Abrahamson reports that he is on the Advisory Board for Novo Nordisk, Boehringer Ingelheim and Halozyme.
Dr. Joshua I. Barzilay reports that he does not have any relevant financial relationships with any
REFERENCES (109)
- et al.
American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine
Endocr Pract
(2012) - et al.
Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study
Lancet
(2005) - et al.
Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
Lancet
(2011) - et al.
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
Am J Clin Nutr
(2012) - et al.
Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists
Endocr Pract
(2008) - et al.
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
Lancet
(2009) Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin-diabetes control and potential adverse events
Best Pract Res Clin Endocrinol Metab
(2009)- et al.
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
Lancet
(2005) Meglitinide analogues: a review of clinical data focused on recent trials
Diabetes Metab
(2006)- et al.
Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis
Diabetes Res Clin Pract
(2008)
Insulin therapy in type 2 diabetes mellitus
Endocrinol Metab Clin North Am
A meta-analysis of alcohol consumption and the risk of 15 diseases
Prev Med
Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial
J Am Coll Cardiol
Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy
J Am Coll Cardiol
Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice
J Clin Lipidol
Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes
Atherosclerosis
Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes
Diabetes
Medical therapy for the patient with obesity
Circulation
Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study
Circulation
Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP)
Obesity (Silver Spring)
Low-dose controlled-release phentermine/topiramate (PHEN/TPM CR) for weight loss and management of type 2 diabetes mellitus (T2DM).In: Program of the 28th annual meeting of the Obesity Society
Endocr Pract
Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study
Obesity (Silver Spring)
Multicenter, placebo-controlled trial of lorcaserin for weight management
N Engl J Med
FDA approves Invokana to treat type 2 diabetes-First in a new class of diabetes drugs. Available at
The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial
Ann Intern Med
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial
Lancet
Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program
Diabetes
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Diabetes Care
Glucose control and vascular complications in veterans with type 2 diabetes
N Engl J Med
Effects of intensive glucose lowering in type 2 diabetes
N Engl J Med
Metformin
N Engl J Med
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
N Engl J Med
Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study
Ann Intern Med
Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes
JAMA
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis
Diabetes Obes Metab
Facilitation of b-cell K(ATP) channel sulfonylurea sensitivity by a cAMP analog selective for the cAMP-regulated guanine nucleotide exchange factor Epac
Islets
Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
Diabetes Obes Metab
Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations
Diabetes Metab Syndr Obes
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies
Eur Heart J
Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies
Diabet Med
Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence
Diabetes Obes Metab
Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes
Diabetes Care
Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes
Diabetes Care
Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes
Am J Health Syst Pharm
Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month ‘proof-of-concept’ study
Diabetes Obes Metab
Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs
Diabetes Obes Metab
The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients
Diabetes Care
A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes
Diabetes Care
Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes
Diabetes Care
Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine
Diabetes Obes Metab
Cited by (180)
Bone marrow-derived mesenchymal stem cells laden novel thermo-sensitive hydrogel for the management of severe skin wound healing
2018, Materials Science and Engineering CTotal iridoid glycoside extract of Lamiophlomis rotata (Benth) Kudo accelerates diabetic wound healing by the NRF2/COX2 axis
2024, Chinese Medicine (United Kingdom)Interactions between diabetic and hypertensive drugs: a pharmacogenetics approach
2023, Molecular Genetics and Genomics